The combination of omega−3 fatty acids with high doses of vitamin D3 elevate A1c levels: A randomized Clinical Trial in people with vitamin D deficiency

Abstract

The High prevalence of vitamin D deficiency (VDD) and type 2 diabetes mellitus (T2DM) among Jordanians spread dramatically during the last decade. 1,2 This was related to an increased risk of T2DM in people with VDD. 3,4 There is no consensus yet about the possible therapeutic effect for VD 3 on glycaemic control in diabetics or prediabetics with VDD. However, some reports have pointed out that VD 3 supplementation may improve glycaemic control in diabetic patients, as well as pre-diabetic people with VDD. 5-7 Nevertheless, inconsistencies have been noted across many randomised controlled trials (RCTs) designed to assess the influence of different doses of VD 3 on glycated haemoglobin (A1c) follow-up levels in people with VDD. [8][9][10][11][12] Several RCTs with different treatment protocols including 4000, 100 000 and 200 00 IU of VD 3 have not shown that VD 3 supplementations can improve A1c levels in T2DM patients. 10,11 On the other hand, the effects of omega−3 fatty acids (n-3FA) on glycaemic control or its correlation with A1c levels may be more ambiguous than the effects of VD 3 supplementation. Previous RCTs generated results that varied considerably and they have shown

The effects of vitamin D and omega-3 co-supplementation on lipid profile in adults: a systematic review and meta-analysis

“…(2017) demonstrated that short-term supplementation with omega-3 and vitamin D in GDM women could decrease TG and VLDL-C. Nevertheless, Barham et al. (2021) did not find any significant effect after supplementation with omega - 3 and vitamin D in vitamin D deficient participants.…”

Assessing the Highest Level of Evidence from Randomized Controlled Trials in Omega-3 Research

“…Conversely, other trials reported a significant reduction in fasting blood glucose, insulin resistance, and HbA1c after supplementing the diet with dosage of n -3 PUFA ranging from 0.41 to 3 g/day for a follow-up of 8 weeks to 1 year as well [ 59 , 60 , 61 , 62 , 63 ] ( Table 3 ). One particular RCT conducted among patients with vitamin D deficiency reported a significant increase in HbA1c in the n -3 PUFA group after 8 weeks of supplementation with 0.3 g of n -3 PUFA daily and 50,000 IU of vitamin D weekly [ 64 ].…”